Cyclops

PureIMS secures new investment round to develop lead inhalation product and facilitate partnering activities

Category: Press release

PureIMS secures new investment round to develop lead inhalation product and facilitate partnering activities

PureIMS today announced it has secured a new investment round. New investor Boost-UP Foundation has joined current shareholders (CardusoCapital venture capital fund, IMDS Medical Devices and LinesBridge Pharma Group) in this round to finance the company’s ambitious growth strategy. Please find the full press release via this link:

PureIMS names Frank Lambert to advance commercialization of its Cyclops™ Dry Powder Inhaler (DPI)

PureIMS names Frank Lambert to advance commercialization of its Cyclops™ Dry Powder Inhaler (DPI)

Roden — February 10, 2023 — PureIMS, a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases, has appointed Frank Lambert to the role of Executive Director Commercialization. DPI developer PureIMS has announced the appointment of Frank Lambert as Executive Director Commercialization. The appointment is part of the […]

PureIMS appoints Jaap Wieling, PhD, as new CEO

PureIMS appoints Jaap Wieling, PhD, as new CEO

Roden — January 7, 2022 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases has appointed Jaap Wieling to the role of Chief Executive Officer (CEO). Dr. Wieling brings 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research […]

PureIMS participating in Biotech Showcase™ 2022

PureIMS aims to find a partner for its lead program Levodopa Cyclops™ Roden — December 22, 2021 — PureIMS today announced that it is participating in Biotech Showcase™ 2022. PureIMS is a clinical stage pharmaceutical and medication systems company developing a portfolio of products addressing acute and unmet medical needs. These products are based on […]

Towards a cure for Mycobacterium abscessus disease using inhaled tigecycline

Roden — July 7, 2021 — Mycobacterium abscessus is a nontuberculous mycobacterium (NTM) that primarily causes severe pulmonary infections. The pathogen is also known as the ‘antibiotic nightmare’, due to its resistance to nearly all antibiotics. Following successful research into a potential treatment option, PureIMS, Radboudumc and Sever Pharma Solutions (until recently known as Disphar […]

PureIMS to present at Biotech Showcase™ Digital 2021

PureIMS preparing for Series A financing round aiming to bring its two lead programs to marketing authorization Roden — December 16, 2020 — PureIMS today announced that it is participating in Biotech Showcase™ Digital 2021, and providing an on-demand company presentation. Bram van Dijck, CEO, will be presenting PureIMS at Biotech Showcase Digital. PureIMS is […]

PureIMS Initiates Phase 1 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of Amikacin for Early Eradication Treatment of Tuberculosis

Delivery via inhaler could dramatically expand Amikacin’s clinical utility by immediate reduction of the contagiousness of Mycobacterium tuberculosis. Roden — July 1st, 2020 — PureIMS, a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory and systemic diseases, announces today the initiation of a Phase 1 clinical trial to evaluate the […]

Hydroxychloroquine Cyclops in Dutch pharmacy magazine ‘Pharmaceutisch Weekblad’

In the fight against COVID-19, PIMS Hydroxychloroquine (subsidiary of PureIMS) – together with (among others) the University of Groningen, UMCG and IMDS – is working feverishly on inhaled hydroxychloroquine. Following pulmonary administration, we expect a much greater effect of the drug with a lower chance of side effects, because it is administered directly to the […]

PureIMS joins the battle against Coronavirus (COVID-19)

In a joint effort with UMCG, University of Groningen and several international partners, PureIMS is actively battling the COVID-19 pandemic by repurposing hydroxychloroquine for pulmonary administration. A first in man trial with Hydroxychloroquine Cyclops™ is in preparation. Nevertheless, it will take months if not longer before this product will become available, if proven effective. We are […]